Global Blood Therapeutics Inc (GBT.OQ)
21 Sep 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|59||2014||President, Chief Executive Officer, Director|
|56||2016||Chief Financial Officer|
|40||2016||Senior Vice President, Operations|
|65||2016||Senior Vice President, Research|
|48||2015||Chief Business and Strategy Officer|
- BRIEF-GBT Signs Licensing Agreement For Inclacumab To Treat Vaso-Occlusive Crisis
- GBT's drug meets trial goal, investors skeptical of speedy approval
- UPDATE 3-GBT's drug meets trial goal, investors skeptical of speedy approval
- Global Blood Therapeutics' sickle cell disease drug succeeds in trial
- BRIEF-GBT Q1 Loss Per Share $0.87